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amplified and/or lIN28+ CNS-PNeTs. We interrogated 
450 pediatric brain tumors using FISH and IHC analyses 
and demonstrate that C19MC alteration is restricted to a 
sub-group of CNS-PNeTs with high lIN28 expression; 
however, lIN28 immunopositivity was not exclusive to 
CNS-PNeTs but was also detected in a proportion of other 
malignant pediatric brain tumors including rhabdoid brain 
tumors and malignant gliomas. C19MC amplified/lIN28+ 
group 1 CNS-PNeTs arose predominantly in children 
<4 years old; a majority arose in the cerebrum but 24 % 
(13/54) of tumors had extra-cerebral origins. Notably, 
Abstract Amplification of the C19MC oncogenic mirNA 
cluster and high lIN28 expression has been linked to a dis-
tinctly aggressive group of cerebral CNS-PNeTs (group 1 
CNS-PNeTs) arising in young children. In this study, we 
sought to evaluate the diagnostic specificity of C19MC and 
lIN28, and the clinical and biological spectra of C19MC 
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group 1 CNS-PNeTs encompassed several histologic 
classes including embryonal tumor with abundant neu-
ropil and true rosettes (eTANTr), medulloepithelioma, 
ependymoblastoma and CNS-PNeTs with variable dif-
ferentiation. Strikingly, gene expression and methylation 
profiling analyses revealed a common molecular signature 
enriched for primitive neural features, high lIN28/lIN28B 
and DNMT3B expression for all group 1 CNS-PNeTs 
regardless of location or tumor histology. Our collective 
findings suggest that current known histologic categories 
of CNS-PNeTs which include eTANTrs, medulloepi-
theliomas, ependymoblastomas in various CNS locations, 
comprise a common molecular and diagnostic entity and 
identify inhibitors of the lIN28/let7/PI3K/mTOr axis and 
DNMT3B as promising therapeutics for this distinct his-
togenetic entity.
Introduction
Primitive neuroectodermal tumors of the central nervous 
system (CNS-PNeT) are a heterogeneous group of pedi-
atric neoplasms composed of poorly differentiated neu-
roepithelial cells with varying degrees of divergent neu-
ral, astrocytic and ependymal differentiation. According 
to the current WHO CNS tumor working classification, 
CNS-PNeTs are grouped into several histologic categories: 
CNS neuroblastoma/ganglioneuroblastoma, medulloepi-
thelioma (MeP), ependymoblastoma (ePB) and classical 
CNS-PNeT (PNeT-NOS) [14]. In 2000, eberhart et al. [4] 
described a new CNS-PNeT variant arising primarily in 
infancy, which displayed histological features of both neu-
roblastoma and ePB, and were distinguished by the pres-
ence of true and pseudo-rosettes on a background of abun-
dant neuropil. These tumors, termed ‘embryonal tumors 
with abundant neuropil and true rosettes’ (eTANTrs), cor-
related with very poor patient prognosis with a mortality 
rate of 76 % and a median survival of 9 months [1, 5, 21].
li et al. [13] first reported C19MC amplification was 
enriched in cerebral CNS-PNeTs with variant histologic 
features including tumors called eTANTr, MeP, ePB and 
PNeTs with atypical features, thus suggesting that these con-
ventional histologic sub-classes may represent closely related 
molecular entities. Indeed, Korshunov et al. [10] reported 
C19MC amplification in 37/40 tumors with a histologic diag-
nosis of eTANTr or ePB. In addition, C19MC amplification 
has been reported in tumors with mixed features of eTANTr 
and MeP [2, 16]. Subsequent studies demonstrated that up-
regulation of the rNA-binding pluripotency gene, LIN28 
[11, 17], correlated closely with C19MC amplification thus 
suggesting that lIN28 may represent an attractive immuno-
diagnostic marker for this distinct molecular sub-group of 
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cerebral CNS-PNeTs. However, the relative diagnostic sig-
nificance of C19MC and lIN28, and the molecular and thera-
peutic relationship of these different histologic sub-classes of 
CNS-PNeTs remain to be completely elucidated.
To identify relevant therapeutic pathways for these 
tumors, we sought in this study to first evaluate the diag-
nostic specificity of C19MC amplification and lIN28 
expression for CNS-PNeTs, and define the histopathologic 
and clinical features of CNS-PNeTs with C19MC ampli-
fication and/or lIN28 expression. We compared global 
gene expression and methylation data from C19MC ampli-
fied and/or lIN28+ CNS-PNeTs with various histologic 
diagnostic labels and anatomic locations, and investigated 
pharmacologic inhibitors of lIN28/let-7/mTOr signaling 
and DNMT3B on growth of a novel cell line derived from a 
non-C19MC amplified group 1 CNS-PNeT.
Materials and methods
Tumor and nucleic acid samples
Tumor specimens and clinical information were col-
lected with consent as per protocols approved by Hospital 
research ethics Board at participating institutions. A total 
of 450 primary pediatric brain tumors with various histo-
logic diagnoses—103 CNS-PNeTs, 45 atypical rhabdoid 
teratoid tumors (ATrTs), 128 medulloblastomas (MBs), 
105 ependymomas (ePNs), 50 high-grade gliomas (Hggs) 
and 20 choroid plexus carcinomas (CPCs) were examined 
in this study (Supplemental Table 1). All ATrTs diagnoses 
were confirmed for genetic alterations of SMARCB1/INI1 
by Multiplex ligation mediated PCr and/or targeted gene 
sequencing and for loss of SMArCB1/INI1/BAF47 protein 
expression by immunostaining. Of the 54 group 1 CNS-
PNeTs examined for detailed histopathologic correlates 
(Table 1 and Supplemental Table 2), 33 were previously 
reported [13, 17]; and 21 additional tumors with a diag-
nosis of CNS-PNeT, eTANTr or embryonal tumor with 
multilayered rosettes (eTMr), MeP and ePB were col-
lected for this study. Three tumors with an initial diagno-
sis of ePB were histologically reviewed and re-classified 
as eTANTr (PNeT 5, 39 and 54). Tumor DNA and rNA 
were extracted by standard methods, quantified using Nan-
oDrop Analyzer, and analyzed using the Illumina HT-12 v4 
gene expression and 450 K Methylation arrays and Omni-
Quad 2.5 M SNP genotyping arrays (http://www.illumina
.com) to generate gene expression, methylation, and copy 
number profiles. Methylation profiling was performed at 
The Centre for Innovation at genome Quebec; all other 
analyses were performed at The Centre of Applied genom-
ics (TCAg) at the Hospital for Sick Children.
Histology, immunohistochemistry and fluorescence in situ 
hybridization
Hematoxylin and eosin (H and e) staining was performed 
using standard protocols. Fluorescence in situ hybridization 
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Table 1  Histopathologic and clinical features of C19MC amplified/lIN28+ CNS-PNeTs
ETANTR embryonal tumor with abundant neuropil and true rosettes, EPB ependymoblastoma, MEP medulloepithelioma, PNET primitive neu-
roectodermal tumor, M0 no metastasis, M+ M1–M3 metastasis as per Chang criteria
a
  Includes PNeT with ependymal and anaplastic features
b
  Only institutional pathology diagnosis available
c
  Pearson Chi-Square
d
  Subset of tumors analyzed on TMAs (including 5/50 for C19MC FISH and 7/40 for lIN28 IHC)
e
  Kruskal–Wallis Test
f
  Includes one patient treated with radiation only
g
  log-rank (Mantel–Cox) test
Total Histologic categories
eTANTr/ePB MeP PNeTa PNeTb
54 22 12 11 9
C19MC statusc,d
 Number analyzed 51 21 12 9 9
  Amplified/overexpressed 43 (84 %) 20 (95 %) 9 (75 %) 7 (78 %) 7 (78 %)
  Not amplified/overexpressed 8 (16 %) 1 (5 %) 3 (25 %) 2 (22 %) 2 (22 %)
lIN28 IHCc,d
 Number analyzed 40 20 10 10 0
  Positive 40 20 10 10 0
C19MC/lIN28 statusc
 Number analyzed 37 19 10 8 0
  C19MC not amplified/lIN28+ 5 (14 %) 1 (5 %) 2 (20 %) 2 (25 %) 0
locationc
 Number analyzed 54 22 12 11 9
  Cerebral hemispheres 41 (76 %) 14 (62 %) 8 (67 %) 10 (91 %) 9 (100 %)
  Non-cerebral 13 (24 %) 8 (38 %) 4 (33 %) 1 (9 %) 0 (0 %)
genderc
 Number analyzed 53 22 12 10 9
  Male:female 24:29 12:10 6:6 4:6 2:7
Age at diagnosis (months)e
 Number analyzed 52 22 12 11 7
  Median (range) 29 (0.5–180) 29 (7–60) 23 (0.5–54) 34 (10–107) 32 (18–180)
Metastatic statusc
 Number analyzed 37 13 10 10 4
  M0:M+ 24:13 8:5 6:4 7:3 3:1
Treatmentc
 Number analyzed 41 18 11 9 3
  Chemotherapy only 20 (49 %) 11 (61 %) 3 (27 %) 5 (56 %) 1 (33 %)
  Chemotherapy and radiationf 11 (27 %) 4 (22 %) 4 (36 %) 2 (22 %) 1 (33 %)
  None 10 (24 %) 3 (17 %) 4 (36 %) 2 (22 %) 1 (33 %)
Survival statusc
 Number analyzed 46 17 12 11 6
  Status (alive:dead) 10:36 4:13 4:8 1:10 1:5
Survival (months)
 Histologic categoriesg
 Number analyzed 36 15 11 10 n/a
  Median survival ± SD (95 % CI) 13 ± 2.0 (9.0–17.0) 10 ± 2.5 (5.1–15.0) 13 ± 6.2 (0.9–25.1) 19 ± 8.6 (2.2–35.8) n/a
Treatmentg Treated Untreated
 Number analyzed 36 30 6
  Median survival ± SD (95 % CI) 12 ± 1.9 (8.3–15.7) 0.1 ± 1.8 (0.0–3.7) 13 ± 1.9 (9.3–16.7)
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(FISH) and immunohistochemistry (IHC) were performed 
on 5-μm formalin-fixed paraffin-embedded (FFPe) sec-
tions for individual tumors or tissue microarrays (TMA). 
TMA construction was as previously detailed [18]. Tumor 
tissue blocks and corresponding slides were reviewed by an 
experienced neuropathologist (CH) for diagnostic accuracy 
and adequacy of tissues; samples that had extensive necro-
sis or <60 % tumor content were discarded. representative 
tumor areas were identified, and three 1-mm tissue cores 
were selected with the goal of obtaining a sampling accu-
racy >95 % for each tumor represented on the TMA [6, 
8]. A variety of tissues including liver, fetal cerebellum, 
placenta, breast carcinoma, and basal cell carcinoma were 
included on each array to serve as internal controls for vari-
ous immuno-stains.
For FISH analyses, pre-labeled BAC probes (http://www. 
tcag.ca/cytogenomics) mapping to chr19q13.42 (rP11-
381e3: 162, 225 bp) and an internal control chr19p13.11 
locus (rP11-451e20: 165,783 bp) were used as described 
previously [13]. For IHC analyses, a heat-induced antigen 
retrieval process was used, followed by blocking endog-
enous peroxidase and biotin. Primary anti-lIN28 (#3978) 
and anti-phospho-S6 (Ser240/244) (#5364) antibodies were 
purchased from Cell Signaling Technology (Boston, MA, 
USA) and anti-DNMT3B (ab13604) was purchased from 
Abcam (Toronto, ON, CA). Antibody reactivity was visual-
ized using the VectaStain ABC detection kit, Vector labo-
ratories (Burlingame, CA, USA).
For each protein, cytoplasmic and/or nuclear immuno-
positivity was visually scored based on both strength (0, 1, 
2, 3–3+) and distribution (<25, 25–50, 51–75, and >75 % 
of tumor cells). Only tumors with strong staining (3–3+) 
in >25 % of tumor cells were considered to be positive. 
Tumors with FFPe slides were scored based on analyses 
of the whole tumor section, while tumors on TMAs were 
assessed on the basis of staining patterns in at least two of 
three tissue cores. Human testicular germ cell tumor tissue 
was used as a positive control for lIN28 staining, while 
sections processed in parallel without primary antibodies 
were used as negative controls. All immunohistochemical 
stains were scored independently by TS, DP, MB and NH, 
and reviewed by AH and CH.
gene expression and methylation array data analyses
gene expression data from 59 primary CNS-PNeTs aris-
ing in different locations were generated using the Illumina 
HT-12v4 arrays and normalized as previously described 
[17]. Methylation data generated using the Illumina 
human 450 k arrays for 45 primary CNS-PNeTs were 
background-normalized in genome Studio (v. 2011.1) to 
obtain beta values for downstream analyses. All X and Y 
chromosome probes (n = 11,649), single-nucleotide poly-
morphisms (dbSNP, n = 88,679), and unannotated probes 
(relative to hg19, n = 65) were excluded leaving a total of 
385,184 probes for methylation analyses. genes and probes 
were ranked by largest coefficient of variation and standard 
deviation, respectively. Unsupervised hierarchical cluster-
ing (HCl; Partek genomics Suite, v6.6) of gene expression 
and methylation data were, respectively, established using 
Pearson’s Dissimilarity performed iteratively on 200–2,000 
genes and 200–10,000 probes to identify a minimal gene 
set associated with the most stable gene expression and 
methylation tumor cluster patterns (Supplemental Fig. 2).
Statistical analyses
Median age at diagnosis was compared using Kruskal–
Wallis test and log rank (Mantel–Cox) analysis was used 
to assess survival. All other clinical and biological charac-
teristics were compared using Pearson Chi-Square (χ2). A p 
value of <0.05 was regarded as significant for all analyses. 
All statistical analyses were done using SPSS version 22.0.
Cell culture and growth assays
To generate stable tumor cell line, A664, a pre-treatment 
primary tumor from a non-C19MC amplified/lIN28+ 
CNS-PNeT (PNeT398) was dissociated by gentle manual 
trituration followed by passage through a 40-μm mesh fil-
ter. Cells were grown in low-adhesion tissue culture flasks 
(Sarstedt, Montreal, QC, CA) in defined serum-free media 
at 37 °C, 5 % CO2. Culture media consisted of human neu-
ral stem cell proliferation media (Stem Cell Technologies, 
Vancouver, BC, CA) supplemented with heparin, epidermal 
growth factor (egF, 10 ng/ml, Sigma Aldrich, St. louis, 
MO, USA), and fibroblast growth factor (FgF, 10 ng/
ml, Stem Cell Technologies, Vancouver, BC, CA). Cells 
were dissociated using Accumax (Millipore, MA, USA) 
by manual trituration and re-plated at ~40 % confluency 
(20,000 cells/ml) and maintained stably for >10 consecu-
tive passages.
 For drug treatment and growth assays, A664 cells 
were plated in 96-well dishes at 2,000 cells/well and incu-
bated overnight. Cells were then treated with rapamy-
cin (Sigma Aldrich, St. louis, MO, USA), 5-azacytidine 
(Sigma Aldrich, St. louis, MO, USA) or vorinostat (Sell-
eckchem, Burlington, ON, CA) and evaluated for changes 
in cell proliferation assays at various days post-treatment 
using CellTiter 96® AQueous One Solution Cell Prolifera-
tion Assay kit (Promega, Madison WI, USA). Viable cell 
numbers were determined based on absorbance at 575 nm 
using a Versamax microplate reader (Molecular Devices, 
Sunnyvale, CA, USA).
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Quantitative real-time (qrT-PCr), western blot and sirNA 
knockdown analyses
For lIN28 knockdown, A664 cells were plated at a density 
of 1.5 × 105 cells/ml in 6-well plates. Scrambled control or 
lIN28-specific sirNA (Fisher Scientific, Ottawa, ON, CA) 
was transiently transfected into cells using lipofectamine 
2000 (life Technologies, Burlington, ON, CA) as per the 
manufacturer’s protocol. Cells were harvested at 48-h post-
transfection for protein extraction and analysis by Western 
blotting. Western blot analysis and chemiluminescence 
detection were performed using standard protocols. Sec-
ondary HrP-linked donkey anti-rabbit or HrP-linked 
sheep anti-Mouse (#NAV934, 931) was from ge Health-
care (Baie-d’Urfe, QC, CA).
For mirNA-specific qrT-PCr, single-stranded cDNA 
was synthesized from 10 ng of rNA using a mir-spe-
cific stem-loop reverse-transcription rT-primer and the 
TaqMan® MicrorNA reverse Transcription Kit (life Tech-
nologies, Burlington, ON, CA). qrT-PCr was performed 
using TaqMan® Universal PCr Master Mix, no Amperase® 
UNg (life Technologies, Burlington, ON, CA) accord-
ing to the manufacturer’s instructions; mirNA expres-
sion levels were normalized relative to rNU6B using the 
ΔCt method, and compared to that of 16-week-old whole 
human fetal brain control.
Results
CNS-PNeTs with C19MC amplification and lIN28 
immunopositivity span a histologic and anatomic spectrum 
of tumors
We [13, 17] and others [10, 11] previously reported fre-
quent amplification of the C19MC oncogenic mirNA 
H&E C19MC FISH anti-LIN28 IHC
ETANTR
PNET67
MEP
PNET255
250 µm
100 µm
PNET
(divergent 
differentiation)
PNET3
50 µm 50 µm
100 µm
200 µm
100 µm 50 µm
PNET-NOS 
PNET161
C19MC (RP11-381E3)
Control (RP11-45E20)
  7 µm
  7 µm
  7 µm
  7 µm
Fig. 1  Histologic spectra of CNS-PNeTs with C19MC amplification 
and lIN28 immunopositivity. representative H and e stains, C19MC 
FISH and lIN28 IHC analyses of CNS-PNeTs with histologic fea-
tures of eTANTr (PNeT67), MeP (PNeT255), CNS-PNeT with 
divergent differentiation (PNeT3) and undifferentiated PNeT-NOS 
(PNeT161)
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cluster and high lIN28 protein expression in an aggres-
sive sub-group of CNS-PNeTs. To comprehensively define 
the clinico-pathologic features of these newly recognized 
molecular entities, we first tested the diagnostic robust-
ness of the C19MC and lIN28 markers in a spectrum of 
pediatric brain tumors for which materials were available 
for central re-review of histopathology and confirmation of 
histologic diagnosis according to the current WHO CNS 
tumor classification criteria. These comprised an institu-
tional cohort of 128 MBs, 45 ATrTs, 105 ePNs, 50 Hggs, 
20 CPCs, and 103 CNS-PNeTs from various institutions; 
450 and 416 samples had materials available for FISH 
and lIN28 IHC analyses. As reported previously, C19MC 
amplification or copy number gains were restricted to and 
detected in 24.3 % (25/103) of CNS-PNeTs, while lIN28 
immunopositivity was observed in 21.4 % (22/103) of 
all CNS-PNeTs. However, in contrast to C19MC ampli-
fication, cytoplasmic lIN28 immunopositivity was not 
restricted to CNS-PNeTs but was also observed in a spec-
trum of other tumors including 24.4 % (11/45) of ATrTs 
and 19.5 % (8/41) of Hggs (Supplemental Table 1). These 
results indicate that lIN28 immunopositivity alone may 
not be sufficient to establish a diagnosis of CNS-PNeTs.
To evaluate the relationship of CNS-PNeTs with 
C19MC amplification and lIN28 positivity to known his-
tologic sub-types of CNS-PNeTs [14], we next conducted 
more detailed evaluation of tumor histopathology and clini-
cal features in an expanded cohort of 54 CNS-PNeTs iden-
tified on the basis of C19MC amplification and/or lIN28 
expression (Table 1, Supplemental Table 2). Interestingly, 
of 45 tumors with complete histopathologic review, 22/45 
(49 %) exhibited ependymoblastic rosettes with neuropil 
consistent with a histologic diagnosis of eTANTr (includ-
ing 3 tumors initially diagnosed as ePBs), 12/45 (26.7 %) 
displayed papillary features characteristic of MeP with 
variable amounts of neuropil and rosette formation, while 
a subset of 11/45 (24 %) tumors lacked characteristic his-
tologic features of eTANTrs, ePBs or MePs but exhibited 
variable differentiation or relatively bland histology com-
patible with classic or CNS-PNeT-NOS (Fig. 1). In addi-
tion to spanning histologic sub-classes, we observed that 
C19MC amplified/lIN28+ CNS-PNeTs also exhibited 
multiple CNS locations; cerebral origins were most com-
mon (41/54; 76 %), but 24 % (13/54) arose in other CNS 
locations including the cerebellum (6/54; 11 %), brain stem 
(5/54; 9 %), pre-sacral space (1/54; 2 %) and optic nerve 
(1/54; 2 %). Of note, 5/37 (14 %) tumors with overlapping 
data on C19MC and lIN28 status exhibited lIN28 posi-
tivity only, without changes in C19MC expression or copy 
number; these tumors were found in each histologic class 
(please see Supplementary Table 2 for details).
Analyses of clinical features showed that 24/37 (65 %) of 
tumors were non-metastatic at diagnosis and arose predomi-
nantly in young children with a median age of 29 months at 
diagnosis. The incidence of tumor metastases, patient demo-
graphics (gender and age) and overall survival did not dif-
fer significantly across histologic classes. Detailed survival 
data available for 36/54 patients indicated a similar highly 
aggressive course with rapid disease progression and death 
for a majority of patients regardless of tumor histologic 
class (Fig. 2a). The median survival for all patients was 
only 12 ± 1.9 months (range of 0–165 months). However, 
patients who received treatment had significantly longer 
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survival as compared to untreated patients (median survival 
of 13 ± 1.9 versus 0.060 ± 1.84 months; Fig. 2b). Notably, 
six patients (5 with specific treatment information) had sub-
stantially longer survival of 38–204 months; three patients 
remained alive at 56, 165 and 204 months (Supplemental 
Table 2). These findings suggest that chemotherapy ± radi-
otherapy treatment may benefit a subset of patients.
C19MC amplified/lIN28+ CNS-PNeTs with various 
locations and histology exhibit common genetic 
and epigenetic signatures
We had previously demonstrated using global gene expres-
sion profiles that C19MC amplified/lIN28+ CNS-PNeTs 
arising in the cerebral hemispheres comprised a molecular 
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class with relative enrichment of primitive neural features 
that was distinct from two other molecular groups (desig-
nated group 2/3) of hemispheric CNS-PNeTs [17]. The 
convergence of clinical phenotypes observed in C19MC 
amplified/lIN28+ tumors with different histologic fea-
tures and anatomic locations, prompted us to investigate 
whether all C19MC amplified/lIN28+ tumors, regardless 
of histology or location, comprised a common molecular 
entity. Indeed, unsupervised hierarchical cluster analyses of 
gene expression data from 22 C19MC amplified/lIN28+ 
tumors, which included five eTANTrs, seven MePs, and 
ten PNeTs from different CNS locations, clustered together 
as a common molecular class distinct from group 2/3 CNS-
PNeTs (Fig. 3a). Similarly, unsupervised cluster analyses 
of global methylation profiles generated from an overlap-
ping cohort of 19 C19MC amplified/lIN28+ tumors, com-
prised of 5 eTANTrs, 5 MePs, and 9 PNeTs from various 
locations, showed they formed a common molecular clus-
ter distinct from the group 2/3 hemispheric CNS-PNeTs 
(Fig. 3b). In keeping with our prior studies of hemispheric 
CNS-PNeTs [13, 17], C19MC amplified/lIN28+ tumors 
with different location and histology also exhibited a gene 
expression signature enriched for pluripotent and neu-
ral cell lineage genes. Notably, all tumors with or without 
C19MC amplification expressed high levels of pluripotent 
genes lIN28/lIN28B, and low levels of neural differ-
entiation genes including the NF1 family of transcription 
factors (Fig. 3c, d). Collectively, our analyses indicate that 
all CNS-PNeTs with C19MC amplification and/or lIN28 
immunopositivity, regardless of histologic sub-class or 
location, share similar molecular and genetic makeup, thus 
indicating they comprise a common biological and diag-
nostic entity.
Candidate therapeutics for C19MC amplified and/or 
lIN28+ CNS-PNeTs
In recent studies, we showed that the lIN28/let7/P13K-
mTOr pathway is up-regulated and can be targeted by 
rapamycin in a C19MC amplified primary eTANTr cell 
line [19]. In addition, we demonstrated that the unique 
methylation landscape of C19MC amplified tumors is in 
part imposed via C19MC-mediated repression of RBL2, 
and consequent up-regulation of DNMT3B [9]. The uni-
fied molecular signature of lIN28+/C19MC amplified 
and non-amplified CNS-PNeT indicated that they may 
share common therapeutic pathways. We observed that 
lIN28/lIN28B and P13K-mTOr components, IgFBP1-
3, which have been linked to a common functional path-
way [20, 22], as well as DNMT3B were enriched in gene 
expression signatures of CNS-PNeTs with or without 
C19MC amplification (Fig. 3d). Consistent with these 
observations, IHC analyses revealed up-regulation of 
phospho-S6 (pS6), an mTOr pathway target, as well as 
DNMT3B in C19MC amplified and non-amplified primary 
tumors (Fig. 4a, b).
To investigate whether pharmacologic inhibitors of 
mTOr and DNA methylation may have therapeutic roles in 
all group 1 CNS-PNeTs, we tested the effects of rapamy-
cin as well pharmacologic inhibitors of DNA methyl trans-
ferase function (5-azacytidine and vorinostat), on growth 
of a tumor cell line (A664) derived from a non-C19MC 
amplified primary cerebral PNeT398. Using quantita-
tive rT-PCr and sirNA-mediated knockdown of lIN28, 
we confirmed that the lIN28/let7/P13K-mTOr axis was 
conserved in A664 cells. Indeed, rapamycin treatment sig-
nificantly inhibited A664 cell growth with concomitant 
down-regulation of pS6 expression (Fig. 5b–d). Similarly, 
we observed that 5-azacytidine and vorinostat significantly 
inhibited A664 cell growth in a dose-dependent manner 
(Fig. 5e, f). Collectively, these data highlight regulators of 
P13K/mTOr signaling, as well epigenomic modifiers, as 
novel promising therapeutic targets for these recalcitrant 
infantile tumors.
Discussion
In prior studies, we identified three transcriptional classes 
of CNS-PNeTs arising in the cerebral hemispheres. Spe-
cifically, we reported that amplification of the oncogenic 
C19MC mirNA locus and/or high expression of lIN28, 
a pluripotency gene, identified a distinctively aggressive 
sub-group of hemispheric tumors, which we called group 
1 tumors [17]. In this study, we demonstrate that C19MC 
amplification and/or lIN28 expression are seen in CNS-
PNeTs with a spectrum of histology and location, and 
Fig. 3  Unified gene expression and methylation signatures for 
C19MC amplified and/or lIN28 + CNS-PNeTs. a, b Unsupervised 
hierarchical cluster analysis was performed on gene expression (a) 
and methylation data (b) generated, respectively, from 59 (Illumina 
HT-12v4 arrays) and 45 (Illumina human 450 k arrays) primary 
CNS-PNeTs. Most stable tumor cluster patterns were achieved with 
a minimal set of 300 genes, and across 500–4000 methylation probes 
(Supplemental Fig. 2) and indicated distinct segregation of C19MC 
amplified/lIN8+ tumors from groups 2/3 CNS-PNeTs, which 
lack either feature. Anatomic location of individual tumors, specific 
CNS-PNeT histology and C19MC genomic status are indicated. c 
Quantitative rT-PCr analyses of C19MC mirNAs: mir-512-3p, 
517a, 517c, 519a, 520g, in a subset of CNS-PNeTs without C19MC 
genomic amplification is shown relative to that of C19MC amplified 
tumors, rNU6B served as control. d genes most highly enriched in 
group 1 versus group 2/3 CNS-PNeTs were identified using a super-
vised t test adjusted for multiple hypothesis testing (false discovery 
rate ≤0.05). Heat map shows relative magnitude of enrichment for 
specific genes with functions in cell lineage, signaling and epig-
enomic regulation at a significance of *q ≤ 0.05. Tumor analyzed by 
qrT-PCr in c are underlined, non-C19MC amplified tumors and the 
C19MC amplified control tumor analyzed are, respectively, shown in 
bold
◂
300 Acta Neuropathol (2014) 128:291–303
1 3
overlapping transcriptional and epigenomic signatures 
that are distinct from that of other molecular sub-types of 
CNS-PNeTs arising in the cerebral hemispheres [13, 17]. 
Specifically, our data suggest that current known histologic 
categories of CNS-PNeTs which include eTANTrs, MePs 
and ePBs which arise in different CNS locations comprise 
common molecular and therapeutic entities.
Our analyses of a large cohort and spectrum of malig-
nant pediatric brain tumors indicate that C19MC amplifi-
cation is exclusively associated with group 1 CNS-PNeTs. 
Specifically, we did not observe high-level DNA copy 
number changes of C19MC in any other malignant pedi-
atric brain tumors with confirmed histopathologic diag-
nostic features of MBs, ATrTs, ePNs, Hggs, and CPCs. 
The pathogenic and diagnostic importance of this locus 
in CNS-PNeTs is further highlighted by recent identifica-
tion of TTYH1:C19MC gene fusions which is associated 
with very high expression of specific C19MC mirNAs 
and suggest C19MC drives oncogenesis in part by facilitat-
ing maintenance and transformation of a very early, neu-
ral compartment [9]. Notably, although we observed cyto-
plasmic lIN28 expression uniformly (100 %) in C19MC 
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amplified CNS-PNeTs, our analyses also revealed cyto-
plasmic as well as nuclear lIN28 staining in a subset of 
MBs, ATrTs, ePNs and Hggs but not CPCs. Similar to 
prior reports of cytoplasmic lIN28 staining in 20–60 % of 
pediatric and adult gliomas [15] and 64 % of ATrTs [3], 
we observed strong lIN28 cytoplasmic staining in up to 
20–25 % of ATrTs and Hggs analyzed (Supplemental 
Tables 1, 3), which contrasts with a report of cytoplasmic 
lIN28 immunostaining exclusively in eTANTrs [11]. The 
reason underlying these discrepant observations is unclear 
and may be related to the limitations of tissue microarray 
analyses to comprehensively capture tumor heterogeneity. 
Thus we propose that a combination of tumor morphol-
ogy, together with cytoplasmic lIN28 immunostaining and 
C19MC genetic status, is needed to robustly distinguish 
group 1 CNS-PNeTs or related embryonal tumors from 
other malignant pediatric brain tumors which may exhibit 
varying lIN28 expression.
Notably, as in our prior study [17], we observed that 
C19MC amplification or copy number gains together with 
high lIN28 expression identified CNS-PNeTs that exhib-
ited predominantly primitive neural histology with varying 
proportions of ependymoblastic rosettes, neural epithelium 
in papillary and pseudo-tubular formation, although such 
features were not necessarily identifiable in all C19MC 
amplified/lIN28+ CNS-PNeT samples examined. We also 
observed that the proportion of cells with C19MC amplifi-
cation and/or lIN28 expression varied across tumor sam-
ples that share group 1 CNS-PNeTs molecular signatures, 
thus indicating that histopathologic analyses may be con-
founded by intra-tumoral heterogeneity which may reflect 
a varying, continuum of differentiation in the tumors. 
Indeed this may also apply to the histopathologic spectrum 
of eTANTrs, ePBs and MePs seen in CNS-PNeTs [7]. 
Although each of these entities are reported to be extremely 
rare, our data suggest that a combination of C19MC ampli-
fication and/or lIN28 expression together with careful 
morphologic assessment of tumor may identify up to 25 % 
of CNS-PNeTs that make up this histogenetic tumor spec-
trum. As these tumors predominantly arise in children 
<4 years of age, they may represent an even higher propor-
tion of brain and other CNS tumors diagnosed in infancy. 
Thus, a diagnostic approach which combines histopatho-
logic assessment together with evaluation of C19MC and 
lIN28 status will be important for capturing the true spec-
tra of this disease. Therefore, we suggest that evaluation 
of C19MC and lIN28 status should be considered for all 
malignant neuroepithelial tumors arising in young children, 
regardless of CNS locations, in a manner similar to the 
diagnostic work-up for ATrTs.
We did not observe significant differences in C19MC 
amplification and lIN28 expression status nor in global 
identifiers based on gene expression and methylation analy-
ses between various histological sub-types of CNS-PNeTs. 
In addition, though trends toward older age and lower inci-
dence of metastasis at diagnosis were observed in tumors 
with a PNeT or variant PNeT diagnosis, no significant 
differences were evident between histological subgroups. 
These subtle distinctions may prove to be clinically relevant 
upon analysis of a larger tumor cohort. Our data suggest 
that the majority of these tumors are localized at presen-
tation, however, interestingly a subset of patients exhibited 
unusual patterns of metastasis including dural invasion and 
spread to extra-neural sites (Supplemental Table 2). Com-
prehensive diagnostic evaluation of large unbiased cohorts 
will be important for revealing disease patterns to inform 
and unify diagnostic work-up and therapeutic approaches 
for these rare tumors.
Consistent with prior studies [11, 17], we observed dis-
mal overall survival in our study cohort with only 3/36 
patients who remain alive 56–204 months after diagnosis. 
Our data suggest a survival benefit for a small proportion 
of patients treated with chemotherapeutic regimes, with or 
without radiotherapy and underscore the need for better 
therapies in this disease. Our recent [19] and current study 
which demonstrates that rapamycin, a PI3K/mTOr inhibi-
tor, significantly inhibits growth of cell lines derived from 
both C19MC amplified and non-amplified primary group 
1 tumors suggests targeting the P13K/mTOr pathway as 
a novel therapeutic avenue for this disease. In this study, 
we also demonstrated that 5-azacytidine, a pharmacologi-
cal antagonist of DNMTs, and HDAC inhibitor, vorinostat, 
had significant effects on A664 cell growth. Together with 
recent demonstration that C19MC regulates the rBl2-
DNMT3B axis [9], our data suggest epigenetic regulators 
as important new therapeutic targets in this disease.
 In summary, our study, together with a recent simi-
lar report by Korshunov et al. [12], indicate CNS-PNeTs 
with C19MC amplification and/or lIN28 expression span 
various histologies but comprise a single molecular disease 
that warrant common therapeutic strategies. Our study pro-
vide novel insights into potential targetable pathways for 
this frequently fatal but relatively uncommon disease and 
report on a unique cell line model that will be an invaluable 
resource for future therapeutic investigations.
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